RBC
PGEN icon

Roble Belko & Company’s Precigen PGEN Stock Holding History

Roble Belko & Company’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10
Closed – – 366
2024
Q1 		$0 Hold
10
– – ﹤0.01% 351
2023
Q4 		$0 Buy
+10
New +$12 ﹤0.01% 343

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Roble Belko & Company's PGEN Position: Q2 2024 in Review

Roble Belko & Company sold out of Precigen (PGEN) in Q2 2024, closing a stake of 10 shares.

Roble Belko & Company first reported a position in PGEN in Q4 2023 and held it in 2 quarters. The position peaked at $0 in Q1 2024. 130 funds tracked by Wall St. Rank hold PGEN as of Q2 2024.

  • Roble Belko & Company reported no remaining Precigen position as of Q2 2024 after selling out during the quarter.
  • Roble Belko & Company sold 10 Precigen shares in Q2 2024.
  • Roble Belko & Company first reported a position in Precigen in Q4 2023 and held it in 2 quarters.
  • Roble Belko & Company's Precigen position peaked at $0 in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Precigen as of Q2 2024.

Based on Roble Belko & Company's 13F filing for Q2 2024, filed 8 Aug 2024.